GlassScriptPhysician profile
Janet I Sanchez
NPI 1962546499
$40,460.55
in general payments reported to CMS, 2019-2025
43 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $4,017 · 2021: $3,504 · 2022: $3,689 · 2023: $3,825 · 2024: $4,496 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,964.11 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,275.90 | 2019-2025 | Evenity, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $5,167.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $2,772.94 | 2021-2025 | |
| Abbvie INC. | $1,422.19 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Scilex Pharmaceuticals INC. | $1,205.87 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,205.13 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $1,203.90 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,056.83 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $998.39 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Allergan, INC. | $559.31 | 2019-2020 | |
| Pfizer INC. | $522.52 | 2019-2025 | |
| Horizon Therapeutics Plc | $518.21 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $490.59 | 2023-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $417.20 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $378.18 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.